Propolis is commonly used in
traditional Chinese medicine. Studies have demonstrated the
therapeutic effects of
propolis extracts and its major bioactive compound
caffeic acid phenethyl ester (CAPE) on
obesity and diabetes. Herein, CAPE was found to have pharmacological activity against
nonalcoholic fatty liver disease (
NAFLD) in diet-induced obese mice. CAPE, previously reported as an inhibitor of bacterial
bile salt hydrolase (BSH), inhibited BSH enzymatic activity in the gut microbiota when administered to mice. Upon BSH inhibition by CAPE, levels of tauro-β-
muricholic acid were increased in the intestine and selectively suppressed intestinal farnesoid X receptor (FXR) signaling. This resulted in lowering of the
ceramides in the intestine that resulted from increased diet-induced
obesity. Elevated intestinal
ceramides are transported to the liver where they promoted fat production. Lowering FXR signaling was also accompanied by increased
GLP-1 secretion. In support of this pathway, the
therapeutic effects of CAPE on
NAFLD were absent in intestinal FXR-deficient mice, and supplementation of mice with
C16-ceramide significantly exacerbated hepatic steatosis. Treatment of mice with an
antibiotic cocktail to deplete BSH-producing bacteria also abrogated the therapeutic activity of CAPE against
NAFLD. These findings demonstrate that CAPE ameliorates
obesity-related steatosis at least partly through the gut microbiota-
bile acid-FXR pathway via inhibiting bacterial BSH activity and suggests that
propolis enriched with CAPE might serve as a promising therapeutic agent for the treatment of
NAFLD.